Share

Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma.

Fernanda Capareli, Frederico Costa, Jack A Tuszynski, Micelange C Sousa, Yone de C Setogute, Pablo D Lima, Luciana Carvalho, Elizabeth Santos, Brenda P Gumz, Jorge Sabbaga, Tiago B de Castria, Denis L Jardim, Daniela Freitas, Natally Horvat, Regis O F Bezerra, Leonardo Testagrossa, Tiago Costa, Tatiana Zanesco, Antonio F Iemma, Ghassan K Abou-Alfa

PAPERpubmedCancer medicine2023OtherEffect: mixedEvidence: Low

Abstract

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) and poor liver function lack effective systemic therapies. Low-energy electromagnetic fields (EMFs) can influence cell biological processes via non-thermal effects and may represent a new treatment option. METHODS: This single-site feasibility trial enrolled patients with advanced HCC, Child-Pugh A and B, Eastern Cooperative Oncology Group 0-2. Patients underwent 90-min amplitude-modulated EMF exposure procedures every 2-4 weeks, using the AutEMdev (Autem Therapeutics). Patients could also receive standard care. The primary endpoints were safety and the identification of hemodynamic variability patterns. Exploratory endpoints included health-related quality of life (HRQoL), overall survival (OS). and objective response rate (ORR) using RECIST v1.1. RESULTS: Sixty-six patients with advanced HCC received 539 AutEMdev procedures (median follow-up, 30 months). No serious adverse events occurred during procedures. Self-limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during EMF exposure was associated with specific amplitude-modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment. Median OS was 11.3 months (95% confidence interval [CI]: 6.0, 16.6) overall (16.0 months [95% CI: 4.4, 27.6] and 12.0 months [6.4, 17.6] for combination therapy and monotherapy, respectively). ORR was 24.3% (32% and 17% for combination therapy and monotherapy, respectively). CONCLUSION: AutEMdev EMF exposure has an excellent safety profile in patients with advanced HCC. Hemodynamic alterations at personalized frequencies may represent a surrogate of anti-tumor efficacy. NCT01686412.

AI evidence extraction

At a glance
Study type
Other
Effect direction
mixed
Population
Patients with advanced hepatocellular carcinoma (Child-Pugh A and B; ECOG 0–2)
Sample size
66
Exposure
medical device (AutEMdev; amplitude-modulated EMF exposure) · 90-min procedures every 2–4 weeks
Evidence strength
Low
Confidence: 74% · Peer-reviewed: yes

Main findings

In 66 patients receiving 539 procedures (median follow-up 30 months), no serious adverse events occurred during procedures; self-limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during exposure was associated with specific amplitude-modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment; median OS was 11.3 months overall and ORR was 24.3%.

Outcomes measured

  • Safety (adverse events during procedures)
  • Hemodynamic variability patterns during EMF exposure
  • Health-related quality of life (HRQoL)
  • Overall survival (OS)
  • Objective response rate (ORR) by RECIST v1.1

Limitations

  • Single-site feasibility trial
  • Patients could also receive standard care (combination therapy vs monotherapy reported)
  • Exploratory endpoints (HRQoL
  • OS
  • ORR)
View raw extracted JSON
{
  "study_type": "other",
  "exposure": {
    "band": null,
    "source": "medical device (AutEMdev; amplitude-modulated EMF exposure)",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "90-min procedures every 2–4 weeks"
  },
  "population": "Patients with advanced hepatocellular carcinoma (Child-Pugh A and B; ECOG 0–2)",
  "sample_size": 66,
  "outcomes": [
    "Safety (adverse events during procedures)",
    "Hemodynamic variability patterns during EMF exposure",
    "Health-related quality of life (HRQoL)",
    "Overall survival (OS)",
    "Objective response rate (ORR) by RECIST v1.1"
  ],
  "main_findings": "In 66 patients receiving 539 procedures (median follow-up 30 months), no serious adverse events occurred during procedures; self-limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during exposure was associated with specific amplitude-modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment; median OS was 11.3 months overall and ORR was 24.3%.",
  "effect_direction": "mixed",
  "limitations": [
    "Single-site feasibility trial",
    "Patients could also receive standard care (combination therapy vs monotherapy reported)",
    "Exploratory endpoints (HRQoL, OS, ORR)"
  ],
  "evidence_strength": "low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "amplitude-modulated electromagnetic field",
    "low-energy EMF",
    "AutEMdev",
    "Autem Therapeutics",
    "hepatocellular carcinoma",
    "feasibility trial",
    "safety",
    "hemodynamic variability",
    "quality of life",
    "overall survival",
    "objective response rate",
    "RECIST v1.1"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 5796

Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma. · Non-native EMF